New drug combo shows promise in Hard-to-Treat cancers
NCT ID NCT02495896
First seen Nov 10, 2025 · Last updated Jun 02, 2026 · Updated 34 times
Summary
This early-phase study tests a new drug (sEphB4-HSA) combined with standard chemotherapy in people with advanced or metastatic solid tumors, including head and neck, pancreatic, lung, and gallbladder cancers. The goal is to find the best dose and check for side effects. About 61 adults with tumors that have spread will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC ADENOCARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Hoag Memorial Hospital Presbyterian
Newport Beach, California, 92663, United States
-
USC / Norris Comprehensive Cancer Center
Los Angeles, California, 90033, United States
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.